InMed Pharmaceuticals to Report Full Year Fiscal 2021 Financial Results and Business Update on September 24, 2021
September 17 2021 - 1:14PM
InMed Pharmaceuticals Inc. (“InMed” or the
“Company”) (Nasdaq: INM), a leader in the manufacturing and
clinical development of rare cannabinoids, will report financial
results for the fiscal year ended June 30, 2021,
on Friday, September 24, 2021.
Conference Call & Webcast*:Friday,
September 24, 2021, at 8:00 AM Pacific Time, 11:00 AM Eastern
TimeUS/CANADA Participant Toll-Free Dial-In Number: +1 (855)
605-1745US/CANADA Participant International Dial-In Number: +1
(914) 987-7959Conference ID: 9373618Webcast:
https://edge.media-server.com/mmc/p/ny89uo2r(*Webcast replay
available for 90 days)
The Company’s full financial statements and
related MD&A for the fiscal year ended June 30, 2021 will
be available at www.inmedpharma.com, www.sedar.com and at
www.sec.gov on September 24, 2021.
About InMed: InMed
Pharmaceuticals is a clinical-stage company developing a pipeline
of cannabinoid-based pharmaceutical drug candidates, initially
focused on the therapeutic benefits of cannabinol (“CBN”) and is
developing IntegraSyn™ to produce pharmaceutical-grade
cannabinoids. The Company is dedicated to delivering new
therapeutic alternatives to patients that may benefit from
cannabinoid-based pharmaceutical drugs. For more information,
visit www.inmedpharma.com.
Investor Contact: Colin ClancySenior Director,
Investor RelationsT: +1 604 416 0999E: cclancy@inmedpharma.com
Edison Group:Joe Green/Laine
YonkerT: +1.646.653.7030/+1.646.653.7035E:
jgreen@edisongroup.com / lyonker@edisongroup.com
Cautionary Note Regarding Forward-Looking
Information:
This news release contains "forward-looking information" and
"forward-looking statements" (collectively, "forward-looking
information") within the meaning of applicable securities laws.
Forward-looking information is based on management's current
expectations and beliefs and is subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements.
Forward-looking information in this news release includes
statements about: reporting financial results for the fiscal year
ended June 30, 2021on September 24, 2021; delivering new
therapeutic alternatives to patients that may benefit from
cannabinoid-based medicines; developing a pipeline of
cannabinoid-based medications, initially focused on the therapeutic
benefits of cannabinol; and, leading the way in the clinical
development of cannabinol.
All forward-looking information herein is qualified in its
entirety by this cautionary statement, and InMed disclaims any
obligation to revise or update any such forward-looking information
or to publicly announce the result of any revisions to any of the
forward-looking information contained herein to reflect future
results, events or developments, except as required by law.
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Mar 2024 to Apr 2024
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Apr 2023 to Apr 2024